| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology |
1 Biocenter Oulu and Research Center for Molecular Endocrinology, WHO Collaborating Centre for Research on Reproductive Health, Oulu; and 2 Department of Pathology, University of Oulu, Oulu, Finland
Estrogens have an important role in the development and progression of breast cancer. 17ß-Hydroxysteroid dehydrogenase type 1 (17HSD1), type 2 (17HSD2), and type 5 (17HSD5) are associated with sex steroid metabolism in normal and cancerous breast tissue. The mRNA expressions of the 17HSD1, 17HSD2, and 17HSD5 enzymes were analyzed in 794 breast carcinoma specimens by using tissue microarrays and normal histologic sections. The results were correlated with the estrogen receptor 
(ER-) and ß (ER-ß), progesterone receptor, Ki67, and c-erbB-2 expressions analyzed by immunohistochemical techniques and with the Tumor-Node-Metastasis classification, tumor grade, disease-free interval, and survival of the patients. Signals for 17HSD1 mRNA were detected in 16%, 17HSD2 in 25%, and 17HSD5 in 65% of the breast cancer specimens. No association between the 17HSD1, 17HSD2, and 17HSD5 expressions was detected. A significant association was observed between ER- and ER-ß (P = 0.02; odds ratio, 1.96) expressions. There was also a significant inverse association between ER- and 17HSD1 (P = 0.04; odds ratio, 0.53), as well as ER- and 17HSD5 (P = 0.001; odds ratio, 0.35). Patients with tumors expressing 17HSD1 mRNA or protein had significantly shorter overall and disease-free survival than the other patients (P = 0.0010 and 0.0134, log rank). The expression of 17HSD5 was significantly higher in breast tumor specimens than in normal tissue (P = 0.033; odds ratio, 5.56). The group with 17HSD5 overexpression had a worse prognosis than the other patients (P = 0.0146). ER- also associated with survival (P = 0.045). Cox multivariate analyses showed that 17HSD1 mRNA, tumor size, and ER- had independent prognostic significance.
This article has been cited by other articles:
|
|
 |
|
  A. Jansson, L. Delander, C. Gunnarsson, T. Fornander, L. Skoog, B. Nordenskjold, and O. Stal Ratio of 17HSD1 to 17HSD2 Protein Expression Predicts the Outcome of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients Clin. Cancer Res., May 15, 2009; 15(10): 3610 - 3616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. KULENDRAN, M. SALHAB, and K. MOKBEL Oestrogen-Synthesising Enzymes and Breast Cancer Anticancer Res, April 1, 2009; 29(4): 1095 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Gaudet, S. Chanock, A. Dunning, K. Driver, L. A. Brinton, J. Lissowska, B. Peplonska, P. Pharoah, and M. Garcia-Closas HSD17B1 Genetic Variants and Hormone Receptor-Defined Breast Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2766 - 2772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Plourde, C. Manhes, G. Leblanc, F. Durocher, M. Dumont, O. Sinilnikova, I. BRCAs, and J. Simard Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer J. Mol. Endocrinol., April 1, 2008; 40(4): 161 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Qiu, M. Zhou, M. Mazumdar, A. Azzi, D. Ghanmi, V. Luu-The, F. Labrie, and S.-X. Lin Structure-based Inhibitor Design for an Enzyme That Binds Different Steroids: A POTENT INHIBITOR FOR HUMAN TYPE 5 17beta-HYDROXYSTEROID DEHYDROGENASE J. Biol. Chem., March 16, 2007; 282(11): 8368 - 8379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A Brown, K. Sayasith, N. Bouchard, J. G Lussier, and J. Sirois Molecular cloning of equine 17{beta}-hydroxysteroid dehydrogenase type 1 and its downregulation during follicular luteinization in vivo J. Mol. Endocrinol., January 1, 2007; 38(1): 67 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Jansson, C. Gunnarsson, M. Cohen, T. Sivik, and O. Stal 17{beta}-Hydroxysteroid Dehydrogenase 14 Affects Estradiol Levels in Breast Cancer Cells and Is a Prognostic Marker in Estrogen Receptor-Positive Breast Cancer Cancer Res., December 1, 2006; 66(23): 11471 - 11477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Husen, K. Huhtinen, T. Saloniemi, J. Messinger, H. H. Thole, and M. Poutanen Human Hydroxysteroid (17-{beta}) Dehydrogenase 1 Expression Enhances Estrogen Sensitivity of MCF-7 Breast Cancer Cell Xenografts Endocrinology, November 1, 2006; 147(11): 5333 - 5339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Jansson, C Gunnarsson, and O Stal Proliferative responses to altered 17{beta}-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors. Endocr. Relat. Cancer, September 1, 2006; 13(3): 875 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Feigelson, D. G. Cox, H. M. Cann, S. Wacholder, R. Kaaks, B. E. Henderson, D. Albanes, D. Altshuler, G. Berglund, F. Berrino, et al. Haplotype Analysis of the HSD17B1 Gene and Risk of Breast Cancer: A Comprehensive Approach to Multicenter Analyses of Prospective Cohort Studies Cancer Res., February 15, 2006; 66(4): 2468 - 2475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Honma, K. Takubo, M. Sawabe, T. Arai, F. Akiyama, G. Sakamoto, T. Utsumi, N. Yoshimura, and N. Harada Estrogen-Metabolizing Enzymes in Breast Cancers from Women over the Age of 80 Years J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 607 - 613. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
